Product image of Miacalcic (Calcitonin) supplied by GNH India

Miacalcic

Active Ingredient:
Calcitonin
Origin:
EU

Miacalcic (Calcitonin)

Calcitonin, the active ingredient in Miacalcic, is a peptide hormone presented as an injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to manage hypercalcemia, osteoporosis, Paget's disease of bone, and bone metastases associated with cancer.

GNH India supplies Miacalcic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Manufacturer / TM Owner

Essential Pharma (M) Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Miacalcic (calcitonin) acts on bone metabolism and calcium regulation, providing therapeutic benefit in several conditions.

  • Hypercalcemia: lowers elevated serum calcium levels and alleviates related symptoms.
  • Osteoporosis: reduces bone resorption, helping to maintain bone density and lower fracture risk.
  • Paget's disease of bone: normalizes abnormal bone remodeling and decreases bone pain.
  • Bone metastases associated with cancer: helps control hypercalcemia of malignancy and may reduce skeletal complications.

How It Works

  • Calcitonin binds to calcitonin receptors on osteoclasts, acting as an agonist that inhibits osteoclast-mediated bone resorption. This reduces the release of calcium from bone into the bloodstream, leading to lower serum calcium concentrations. The hormone also promotes renal calcium excretion and modulates calcium handling in the gastrointestinal tract, contributing to its overall hypocalcemic effect.

Side Effects

Calcitonin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Nausea: mild stomach upset often occurring shortly after injection.
  • Flushing: transient warmth and redness of the skin.
  • Headache: mild to moderate pain in the head region.
  • Injection site reactions: pain, erythema or swelling at the administration site.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Severe hypocalcemia: markedly low calcium levels that can cause muscle cramps or seizures.
  • Cardiac arrhythmia: irregular heart rhythm potentially linked to electrolyte disturbances.

Precautions & Warnings

When using Miacalcic, several precautionary measures should be observed to ensure safety.

  • Renal impairment: monitor serum calcium and adjust therapy as needed.
  • Hypersensitivity: discontinue use if signs of allergic reaction appear.
  • Pregnancy: prescribe only if potential benefits outweigh potential risks to the fetus.
  • Concomitant calcium supplements: avoid unless specifically directed by a healthcare professional.
  • Elderly patients: start with lower doses and monitor for adverse effects closely.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Calcitonin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Calcium supplements: may diminish the hypocalcemic effect of calcitonin.
  • Bisphosphonates: combined use can increase the risk of profound hypocalcemia.
  • Loop diuretics: can exacerbate calcium loss leading to severe hypocalcemia.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may reduce calcitonin’s effectiveness on bone resorption.
  • Thyroid hormones: can interfere with calcium metabolism and require monitoring.
  • Anticoagulants: when calcitonin is given intravenously, monitor coagulation parameters.

Frequently Asked Questions

Miacalcic is indicated for the management of hypercalcemia, osteoporosis, Paget's disease of bone, and bone metastases associated with cancer. In each of these conditions, calcitonin helps to lower elevated calcium levels, reduce bone turnover, and alleviate related symptoms.

Calcitonin binds to specific receptors on osteoclasts, the cells responsible for bone breakdown. By activating these receptors, it suppresses osteoclast activity, decreasing bone resorption and the release of calcium into the bloodstream. The hormone also enhances renal calcium excretion, contributing to lower serum calcium concentrations.

The dose and frequency of Miacalcic are determined by the prescribing healthcare professional based on the individual patient's condition, severity, renal function, and response to therapy. No universal dosing schedule is provided; clinicians tailor the regimen to achieve optimal clinical outcomes.

The safety of calcitonin in pregnancy and lactation has not been definitively established. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Miacalcic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Both calcitonin and bisphosphonates inhibit bone resorption, but they act via different mechanisms. Calcitonin provides a rapid, short‑term reduction in serum calcium and is often used for acute hypercalcemia, whereas bisphosphonates have a longer‑lasting effect on bone density and are commonly used for chronic osteoporosis management.

Miacalcic should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Miacalcic is supplied as an injectable solution and may be given intramuscularly, intravenously, or subcutaneously according to the prescriber's instructions. The route, injection site, and volume are selected based on the clinical indication and patient-specific factors.

The most serious adverse events include severe hypocalcemia, which can lead to muscle cramps, seizures, or cardiac arrhythmias, and anaphylactic reactions that require immediate emergency treatment. Patients should be monitored for signs of these conditions, especially after the first dose.

Miacalcic is contraindicated in individuals with known hypersensitivity to calcitonin or any component of the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled hypocalcemia, or those who have experienced serious allergic reactions to similar peptide hormones.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Calcitonin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT